# Questions From the Research Record > Research Peptide FAQ — BPC-157, Semaglutide, Thymosin Alpha-1, CJC-1295, MOTS-c — Definitive Peptides — Frequently asked questions about five Research Peptide Fundamentals research peptides — BPC-157, semaglutide, thymosin alpha-1, CJC-1295 and MOTS-c — answered from the cited literature. **RESEARCH PEPTIDE FUNDAMENTALS / FAQ** Direct, citation-anchored answers to what people most often search about these five compounds. ## What does BPC-157 do in the body? In animal studies, BPC-157 promotes the growth of new blood vessels (angiogenesis) through the VEGFR2-Akt-eNOS pathway, which is the mechanism most consistently linked to its reported tissue-repair effects on tendons, ligaments and gut lining [4]. It has also been shown in rodents to accelerate healing of gastric ulcers and a fully transected Achilles tendon [5][6]. Human data are limited to a small IV safety pilot in two adults, which found no adverse effects but did not test whether it works [1]. ## Is BPC-157 a growth hormone? No. BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric-juice protein, structurally unrelated to growth hormone or to growth-hormone-releasing hormone. Its reported tissue-repair effects are attributed mainly to angiogenesis and cytoprotection rather than to any growth-hormone pathway, though one proposed route involves sensitizing growth-hormone receptors in tendon fibroblasts specifically — a narrower, local effect, not a systemic GH increase. ## Does BPC-157 work immediately? There is no published human efficacy data establishing a timeline for BPC-157, immediate or otherwise — a 2025 review found only three small human pilot studies exist, none designed to measure onset of effect [2]. In animal studies, effects such as ulcer healing and tendon repair were measured over days to weeks, not immediately. Reports of fast-feeling changes circulating in research communities are anecdotal, not clinical evidence. ## Does BPC-157 damage the liver? The only published human safety data — an IV pilot in two healthy adults dosed up to 20 mg — found no measurable change in hepatic biomarkers [1]. That is reassuring but far too small a sample to rule out liver effects at scale or over time. A 2025 review of the literature notes that human safety data overall remain extremely limited and recommends treating BPC-157 as investigational [2]. ## What is semaglutide? Semaglutide is a synthetic peptide that mimics GLP-1, a gut hormone the body releases after eating. It is FDA-approved for type 2 diabetes, chronic weight management, reducing cardiovascular events in people with established heart disease and obesity, and, since 2025, a form of fatty liver disease. It is given as a once-weekly injection or a once-daily oral tablet. ## What is semaglutide used for? FDA-approved uses include lowering blood glucose in type 2 diabetes, reducing body weight in chronic weight management, and reducing major cardiovascular events in adults with established cardiovascular disease and overweight or obesity [10]. In a landmark kidney-outcomes trial, it also reduced the risk of major kidney-disease events by 24% in people with type 2 diabetes and chronic kidney disease [9]. ## How does semaglutide work? Semaglutide activates GLP-1 receptors throughout the body. At the pancreas, it boosts glucose-dependent insulin release and suppresses glucagon; in the gut, it slows how quickly the stomach empties; in the brain, it reaches appetite circuits in the hypothalamus and brainstem that regulate hunger and fullness. Its long, roughly week-long circulating half-life comes from a fatty side chain that binds to albumin in the blood, protecting it from rapid breakdown. ## How does semaglutide work for weight loss? The weight-loss effect is thought to be primarily central: semaglutide reaches hypothalamic and brainstem circuits that activate fullness signals and suppress hunger signals, reducing overall food intake and, according to research-community reports, the background preoccupation with food some call "food noise." In the STEP 1 trial, this produced a mean body-weight change of -14.9% at 68 weeks versus -2.4% with placebo [11]. ## What is thymosin alpha 1? Thymosin alpha-1 (thymalfasin) is a 28-amino-acid immune-modulating peptide, cleaved from a larger precursor protein, that helps mature dendritic cells and coordinate the immune system's T-cell response. It is approved as a drug in more than 35 countries — mainly for chronic viral hepatitis — though it has never received US marketing approval [14]. ## What does thymosin alpha 1 do? It signals through Toll-like receptors on dendritic cells and monocytes, driving their maturation and improving antigen presentation, which helps the immune system mount a more coordinated response. It also has a separate, counterbalancing regulatory arm that can generate regulatory T cells, which is why it is described as both immune-restoring and anti-inflammatory depending on context. Its largest recent trial, in sepsis, found no mortality benefit, showing this dual mechanism does not guarantee benefit in every acute-illness setting [13]. ## What is thymosin alpha 1 used for? Internationally, thymalfasin is used mainly as an adjunct treatment for chronic viral hepatitis, and has been studied as an immune-support adjunct in certain cancers and infections [16]. A retrospective cohort of 76 patients with severe COVID-19 found it associated with significantly lower mortality, though this is observational evidence, not a randomized trial [15]. It is not approved for any indication in the United States. ## Is thymosin alpha 1 FDA-approved? No. Thymosin alpha-1, marketed abroad as thymalfasin, is approved in more than 35 other countries but has no US marketing approval [14]. In the US it is available only in investigational or compounding contexts, and its most rigorous recent trial — a 1,106-patient phase-3 sepsis study — found no significant mortality benefit [13]. ## What is CJC-1295? CJC-1295 is a lab-modified, long-acting analog of growth-hormone-releasing hormone (GHRH). It comes in two forms: a long-acting "DAC" version that binds to a blood protein and lasts several days, with a measured half-life of 5.8 to 8.1 days, and a short-acting "no-DAC" version that lasts only minutes to hours [21]. Neither is approved for human use anywhere. ## What does CJC-1295 do? It binds the GHRH receptor on the pituitary gland, stimulating the release of growth hormone and, downstream, IGF-1. In a study of healthy adults, single doses produced 2- to 10-fold increases in plasma growth hormone lasting six days or more, with IGF-1 elevated for 9 to 11 days [21]. Research also shows the body's natural pulsatile pattern of GH release is preserved rather than flattened by continuous stimulation [22]. ## Is CJC-1295 safe? It is not approved for human use anywhere, and published human evidence is limited to a small number of early pharmacology studies with no long-term safety data [21]. In 2024, FDA briefing materials for a pharmacy-compounding advisory committee cited immunogenicity and other safety concerns as part of the basis for not recommending it for compounding [18]. This site does not characterize CJC-1295 as either safe or unsafe for individual use — that determination requires a licensed clinician. ## How much CJC-1295 should I take? This site does not recommend a dose for any individual — that is not something a research digest can responsibly answer, and CJC-1295 is not an approved medicine with a labeled human dose. For context only: published human pharmacology studies tested single subcutaneous doses of 30 to 90 micrograms per kilogram in healthy adults under controlled research conditions, not as a treatment recommendation for self-administration [21][22]. ## What does the MOTS-c peptide do? In cell and mouse studies, MOTS-c activates AMPK, a master metabolic switch, improving glucose uptake and insulin sensitivity, primarily in skeletal muscle [25]. A 2024 study found it also directly binds and activates an enzyme called casein kinase 2 in a tissue-specific way, which is linked to preventing muscle wasting and improving muscle glucose uptake in mice [23]. There is no published human trial testing whether administering MOTS-c to people produces these effects. ## What are the negative side effects of MOTS-c? There is no published human interventional trial data on MOTS-c, so no documented human side-effect profile exists to report. What the literature does establish are open safety questions: no measured human pharmacokinetics or dose-response, no FDA approval for any use, and unregulated research-chemical product quality that is not verified for purity or identity outside formal studies. Anecdotal reports of side effects circulating in research communities are not backed by controlled human data. ## Is MOTS-c legal to buy? MOTS-c is not approved by the FDA for any use and is sold only as a research chemical labeled not for human consumption. It is also treated as a prohibited substance in elite sport by anti-doping authorities. This site does not advise on the legality of purchasing or possessing MOTS-c in any jurisdiction; that depends on local law and is a question for legal counsel, not a research digest. ## How often do you inject MOTS-c? There is no established human dosing schedule for MOTS-c, because no human interventional trial testing administered doses has been published. Mouse studies cited in the literature used varying protocols to demonstrate exercise-mimetic effects on performance and metabolism [26], but rodent dosing schedules cannot be responsibly extrapolated to a human injection frequency, and this site does not recommend one. --- Definitive Peptides is an independent research desk that traces every claim on this site to a cited source — not a clinic, not a supplier, and never a substitute for a licensed clinician's judgment.